About Us
Our Science
Newsroom
- Press Releases
- Events & Presentations
Investor Relations
Contact

Financial Information

Overview
Corporate Governance
Financial Information
Annual Reports & Proxy Statements
Investor Contact Information

SEC and XBRL Filings »

Quick Links

Home
About Us
Our Science
Newsroom
Investor Relations
Contact

Contact

ir@panbela.com

Sign up to receive press releases via email:

Leave this field empty if you're human:

News & Events

Panbela Announces Pricing of Approximately $6 Million Public Offering

Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Provides Business Update and Reports Q2 2022 Financial Results

Copyright ©2022 Panbela Therapeutics, Inc. All Rights Reserved.